Terlipressin

Overview

Terlipressin is a synthetic vasopressin analog and prodrug designed for selective splanchnic vasoconstriction with reduced systemic vasopressor effects compared to vasopressin. FDA-approved in 2022 for hepatorenal syndrome type 1 (HRS-1) and widely used in Europe for esophageal variceal bleeding, terlipressin is cleaved in vivo to lysine-vasopressin, which acts on V1a receptors to produce prolonged, preferential splanchnic vasoconstriction. This reduces portal hypertension, limits variceal bleeding, and in HRS-1 improves renal perfusion by redirecting blood flow from the splanchnic circulation.

Mechanism of Action

Terlipressin is a prodrug metabolized by endopeptidases to lysine-vasopressin, which binds V1a receptors (vascular smooth muscle) with high affinity, stimulating Gq/11-phospholipase C-IP3-calcium signaling and strong vasoconstriction. Splanchnic arterioles are highly sensitive to V1a activation, resulting in splanchnic vasoconstriction that reduces portal venous inflow, lowers portal pressure, and compresses varices. This hemodynamic shift also redirects blood flow to the systemic circulation, improving renal perfusion in the setting of HRS-1 where renal vasoconstriction is triggered by splanchnic vasodilation.

Potential Benefits

• FDA-approved treatment for hepatorenal syndrome type 1
• Variceal bleeding control (EU approved)
• Selective splanchnic vasoconstriction reducing portal pressure
• Improved renal perfusion in HRS-1 (reduces need for dialysis)
• Longer duration of action than vasopressin (bolus dosing possible)

Research Dosage Notes

The following reflects doses used in published research studies. This is not medical advice.

HRS-1 (FDA approved): 0.85 mg IV q6h, titrated up to 1.0 mg q6h if no response. Variceal bleeding (EU): 1-2 mg IV bolus q4-6h for up to 5 days.

Amino Acid Sequence

Side Effects & Safety

• Hyponatremia
• Abdominal cramps and diarrhea
• Peripheral ischemia (skin, fingers) at high doses
• Hypertension
• Rare: mesenteric ischemia

Synergistic Compounds

The following compounds have been studied alongside Terlipressin for potential complementary or synergistic effects:

Related Peptides

Learn More

References & Further Reading

• [object Object]
• [object Object]